BioSpace News Archive

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today provides a review of its 2023 achievements and a preview of plans for advancing its diabetes and oncology gene therapy programs in 2024.

DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, announced the appointment of Susan Tousi as Chief Executive Officer.

Neurogene Inc. (NASDAQ: NGNE) (“Neurogene” or “the Company”), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, announced today a business update and provided its outlook for 2024.

SimBioSys®, a trailblazing TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and biophysical modeling to redefine cancer precision medicine, transform patient care and defeat cancer today announced the strategic appointment of Jyoti Palaniappan as Chief Commercial Officer (CCO).

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of stock options to purchase 19,251 shares of its common stock to six new employees.

AngioDynamics, Inc. (NASDAQ: ANGO) today announced financial results for the second quarter of fiscal year 2024, which ended November 30, 2023.

Florida Cancer Specialists & Research Institute, LLC announces plans to re-examine its partnerships with distributors and suppliers in 2024, further strengthening scalability efforts driven by its newly established management services organization.

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the Company’s four pillars and outlook for 2024.

MAIA Biotechnology, Inc. today announced its participation in the Biotech Showcase ™ 2024 investor conference being held January 8-10, 2024, in San Francisco, California.

GordonMD ® Global Investments LP, a key investor in groundbreaking healthcare solutions, announced another strategic investment in Radionetics Oncology.